[Government-Enterprise Exchange | Leaders from the Municipal Medicine and Medical Device Office Visit Shenzhen-Hong Kong Cell Valley]

On July 22, 2025, Liu Chuwen, Member of the Party Leadership Group of the Shenzhen Municipal Development and Reform Commission and Director of the Municipal Medicine and Medical Device Industry Office; Sha Sha, Head of Group II of the Shenzhen Municipal Medicine and Medical Device Office; Zhao Yichen from the Second Division of Strategic Emerging Industries of the Shenzhen Municipal Development and Reform Commission; and Lin Taide, Level-1 Administrative Director of the Science and Technology Innovation Division of the Qianhai Administration, among others, visited Shenzhen-Hong Kong Cell Valley for research and inspection. Professor Shi Yuanyuan, Founder of Shenzhen-Hong Kong Cell Valley, accompanied the delegation throughout the visit, comprehensively showcasing the valley's innovative achievements and industrial layout across the entire cell technology industry chain.

Accompanied by Professor Shi Yuanyuan, the visiting delegation toured the Smart Exhibition Hall of Shenzhen-Hong Kong Cell Valley. The tour systematically introduced the valley's technical strengths and industrial practices, covering core segments such as cell storage, preparation, and clinical translation. Highlights ranged from cutting-edge applications of NK cells, stem cells, and exosomes to the establishment of compliance systems and the collaborative innovation model integrating industry, academia, research, and healthcare.

During the inspection, Professor Shi Yuanyuan provided a detailed overview of the Cell Valley Group's current industrial layout, future development direction, and practices in transforming scientific and technological achievements. He stated that Shenzhen-Hong Kong Cell Valley will fully leverage the policy advantages of Qianhai's "multi-zone superposition" to accelerate the industrialization of cell and gene therapy technologies. Currently, the company has initiated clinical collaborations with dozens of top-tier Grade A tertiary hospitals, pushing multiple cell therapy products into clinical trial stages. Director Liu Chuwen spoke highly of Shenzhen-Hong Kong Cell Valley's focus on building cell industry platforms and its development path that adheres to both compliance and innovation. He pointed out that as a key track in the bio-economy, the cell industry must persist in innovation-driven development and continuously break through critical technical bottlenecks. Regarding issues such as clinical translation of cell therapies and collaborative industrial innovation, both sides engaged in deep exchanges on the connection points between policy support and industrial needs, providing strategic guidance for the future development of the Cell Valley Group.

This visit not only signifies recognition of Cell Valley's deep commitment to cell technology but also highlights Shenzhen's determination to cultivate new quality productive forces and seize the commanding heights of the bio-economy. In the future, Shenzhen-Hong Kong Cell Valley will set sail with policy as its wind and row with innovation as its oar, accelerating the clinical translation and industrial landing of cell technologies. By joining hands with industry partners to create a source of innovation for the cell industry, it aims to inject "cell power" into the high-quality development of Shenzhen's biopharmaceutical sector.